Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.47
+0.40 (5.66%)
At close: May 8, 2026, 4:00 PM EDT
7.10
-0.37 (-4.95%)
After-hours: May 8, 2026, 6:36 PM EDT
Gyre Therapeutics Employees
Gyre Therapeutics had 625 employees as of December 31, 2025. The number of employees increased by 46 or 7.94% compared to the previous year.
Employees
625
Change (1Y)
46
Growth (1Y)
7.94%
Revenue / Employee
$187,278
Profits / Employee
-$10,179
Market Cap
682.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 625 | 46 | 7.94% |
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Allogene Therapeutics | 152 |
| Sutro Biopharma | 137 |
| Solid Biosciences | 121 |
| Alpha Tau Medical | 121 |
| Aclaris Therapeutics | 73 |
| Zevra Therapeutics | 61 |
| Relmada Therapeutics | 17 |
| Tenax Therapeutics | 16 |
GYRE News
- 2 days ago - Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year - TheFly
- 3 days ago - Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics’ liver fibrosis candidate granted priority review in China - TheFly
- 7 weeks ago - Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 2 months ago - Gyre Therapeutics reports Q4 EPS (2c), consensus 1c - TheFly
- 2 months ago - Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M - TheFly
- 2 months ago - Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire